Therapeutic targets of formononetin for treating prostate cancer at the single-cell level

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Prostate cancer is a heterogeneous disease affecting older males, necessitating novel therapeutic strategies.
• Targeting gene candidates at the single-cell level offers a promising approach for prostate cancer treatment.
• Understanding molecular alterations is crucial for developing effective interventions.

Purpose of the Study:

• To analyze single-cell sequencing data to identify differential gene expression in prostate cancer.
• To determine therapeutic targets of formononetin in prostate cancer immune and tissue cells using network pharmacology.
• To validate the therapeutic potential of formononetin in human prostate cancer cells.

Main Methods:

• Single-cell sequencing data analysis from previous reports.
• Network pharmacology for identifying therapeutic targets of formononetin.
• Molecular docking to assess formononetin's binding to target proteins.
• Validation using formononetin-treated human prostate cancer cell line DU145.

Main Results:

• Identified differential gene expression clusters, including immunoglobulin kappa C, as potential prostate cancer biomarkers.
• Network pharmacology revealed formononetin targets like CD74 and THBS1 involved in immune cell function.
• Formononetin targets insulin receptor (INSR) and zinc-alpha-2-glycoprotein, crucial for tissue cell metabolism.
• Molecular docking confirmed direct binding of formononetin to INSR, TNF, and CXCR4.

Conclusions:

• Formononetin demonstrates potential as a novel therapeutic agent for prostate cancer.
• Targeting specific cell types at a single-cell level with formononetin offers a new treatment strategy.
• Identified novel biomarkers and therapeutic targets for improved prostate cancer prognosis and management.